Navigation Links
Novavax Reports Fourth Quarter and 2008 Year-End Financial Results
Date:3/31/2009

mmission.

Forward Looking Statements

Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials, including possible delays initiating or completing the trials and safety and immunogenicity results; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-lookin
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Novavax Announces Release Date of 2007 Fourth Quarter, Full Year Financial Results and Investor Conference Call
2. Novavax CEO to Present at the Partnering for Global Health Forum
3. Novavax CEO to Present at Susquehannas Second SIGnificant Options in Healthcare Conference
4. Novavax Announces Release Date of 2007 Third Quarter Financial Results and Investor Conference Call
5. Novavax and Allergan Terminate Manufacturing Supply Agreement for Estrasorb
6. Novavax CEO to Present at the 2007 UBS Global Life Sciences Conference
7. Cadus Reports 2008 Results
8. Nephros Reports 2008 Fourth Quarter and Full Year Financial Results
9. Cardiogenesis Reports Fourth Quarter and Fiscal Year 2008 Results
10. Tiens Biotech Group (USA) Reports Record Twelve-Month Results
11. ULURU Inc. Reports Financial Results for Fourth Quarter and Year Ended December 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... new UCLA study has shown this is definitely the case ... how to treat their prostate cancer. , UCLA researchers found ... a much more difficult time making treatment decisions, called decisional ... their care and their long-term outcomes. , The study should ... the findings to target men less likely to know a ...
(Date:8/27/2014)... Co-operative Research Centre into Microtechnologies, is coordinating ... innovative solutions based on microtechnologies to tackle ... life sciences, among others. IK4-Ikerlan, Ceit-IK4, IK4-Tekniker, ... with CIC microGUNE on this project, which ... Etortek 2013-2014 programme of the Government of ...
(Date:8/27/2014)... 10 portions a week of tomatoes have an 18 ... research suggests. , With 35,000 new cases every year ... is the second most common cancer in men worldwide. ... experts believe is linked to a Westernised diet and ... recommendations reduces risk of prostate cancer, researchers at the ...
(Date:8/27/2014)... This news release is available in German . ... need for medical agents to treat metastatic tumors. In case ... cancer that is often detected late, 95% of the patients ... amcure develops tumor therapeutic agents that might reduce this mortality ... has now received a total of EUR 5 million from ...
(Date:8/27/2014)... CA (PRWEB) August 27, 2014 Bedros Keuilian ... franchise in the world, the leading fitness boot camp ... TV’s Gym Rescue reality series. One thing he knows very ... as a subject matter expert in the fitness business. , ... YouTube, he lays out a step-by-step instructional guide on how ...
Breaking Medicine News(10 mins):Health News:Men who are uneducated about their prostate cancer have difficulty making good treatment choices 2Health News:Men who are uneducated about their prostate cancer have difficulty making good treatment choices 3Health News:Microtechnologies for driving forward mobility and human health 2Health News:Fighting prostate cancer with a tomato-rich diet 2Health News:Preclinical development of tumor therapeutic agent starts 2Health News:Bedros Keuilian Releases New Fitness Boot Camp Marketing Webinar on Building a Personal Brand 2Health News:Bedros Keuilian Releases New Fitness Boot Camp Marketing Webinar on Building a Personal Brand 3
... EP MedSystems,(Nasdaq: EPMD ) announces the following Webcast: What: ... 4:30 pm EST, Where: http://www.videonewswire.com/event.asp?id=43653 , How: ... web at the ... 856-753-8533, If ...
... in related literature. One extremely rare case was recently ... Journal of Gastroenterology because of its maximum diameter of ... clinical and histopathological findings, diagnostic methods and treatment by ... , The article reported one patient who presented to ...
... OCTOBER 25, 2007 Shire plc (LSE: ... biopharmaceutical company, announced that data from a 12-month ... Deficit Hyperactivity Disorder (ADHD) patch, demonstrated that DAYTRANA ... in children aged 6 to 12 years. ...
... formation of a cancer is proven to be a ... a definite carcinogen, the role of Helicobacter pylori (H ... unclear. An article to be published on November 7 ... mechanism explaining the promotional effect of H pylori on ...
... Oct. 26 /PRNewswire-FirstCall/ - Transition Therapeutics Inc.,("Transition") (NASDAQ: ... of US$7.5,million representing the second half of the ... agreement with a subsidiary of,Elan Corporation, plc ("Elan") ... drug,candidate ELND-005/AZD-103. ELND-005/AZD-103 has completed Phase I ...
... 500 health ... plans on quality of care, service, WASHINGTON, Oct. 26 ... Assurance (NCQA) today unveiled the third,edition of America,s Best Health ... plans. Coinciding with the,November launch of "open season," when many ...
Cached Medicine News:Health News:Webcast Alert: EP MedSystems Announces EP MedSystems Third Quarter 2007 Earnings Conference Call Webcast 2Health News:The largest colonic lipoma to date 2Health News:Long-term 12-month safety data on ADHD patch DAYTRANA 2Health News:Helicobacter pylori inhibits intercellular communication of cultured gastric cells 2Health News:Transition Therapeutics Receives Remaining Upfront Payment from Elan Corporation, plc 2Health News:U.S.News & World Report, NCQA Release Annual Rankings for 'America's Best Health Plans' 2Health News:U.S.News & World Report, NCQA Release Annual Rankings for 'America's Best Health Plans' 3
(Date:8/26/2014)... Aug. 26, 2014  Actavis plc (NYSE: ACT ... Brenton Saunders , CEO and President of Actavis, will ... the Morgan Stanley Global Healthcare Conference 2014 in ... The presentation will take place on ... the Grand Hyatt New York, 109 East 42 nd ...
(Date:8/26/2014)... , Aug. 26, 2014 Reportlinker.com ... is available in its catalogue: ... 2020 http://www.reportlinker.com/p02280977/Japan-Esophagoscopes--Gastroscopes-Market-Outlook-to-2020.html ... Outlook to 2020 Summary GlobalData,s ... Outlook to 2020", provides key market data ...
(Date:8/26/2014)... Research and Markets  has announced the ... 2014-2018" report to their offering. Intranasal ... the administration of drugs for the treatment of local ... allergic and non-allergic rhinitis and sinusitis. The nose is ... vaccination and systematic drug delivery. Continuous ...
Breaking Medicine Technology:Actavis to Present at Morgan Stanley Global Healthcare Conference 2014 2Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 2Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 3Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 4Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 5Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 2Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 3
... 2011 , The deadly E. ... thousands across Europe has been sequenced using 454,Life Sciences, ... and detailed genetic analysis to date" of this,particularly virulent ... performed by scientists at the UK,s Health,Protection Agency and ...
... 2011 Reportlinker.com announces that a ... in its catalogue: ... Number of PE/VC Investments in Small ... in the Past Four Years ...
Cached Medicine Technology:Deadly E. Coli Strain Sequenced With Roche GS Junior System by HPA Scientists - Provides Community Most Complete Assembly to Date 2Deadly E. Coli Strain Sequenced With Roche GS Junior System by HPA Scientists - Provides Community Most Complete Assembly to Date 3Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 2Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 3Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 4Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 5Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 6Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 7Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 8Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 9Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 10Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 11
A system with integrated pupil camera and 7" examination monitor. An easy to use configuration....
... The Laserex Tango ophthalmic laser system ... an SLT laser and a photodisruptor for ... is a frequency-doubled Nd:YAG producing pulsed 532 ... Nd:YAG producing 1064 nm. The appropriate laser ...
... is the unique combination laser system for ... of a button switch between SLT or ... Selecta Duet affords you the opportunity to ... the same setting with the benefits inherent ...
Extremely thin and smooth jaws, jaws open to 5.5 mm, cross action....
Medicine Products: